Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Open accessThe DOI matches its Crossref record; 142 of the 149 references it cites were found in a registry or an index.
Abstract
Approximately 25% of US adults are estimated to have hypertriglyceridemia (triglyceride [TG] level ≥150 mg/dL [≥1.7 mmol/L]). Elevated TG levels are associated with increased cardiovascular disease (CVD) risk, and severe hypertriglyceridemia (TG levels ≥500 mg/dL [≥5.6 mmol/L]) is a well-established risk factor for acute pancreatitis. Plasma TG levels correspond to the sum of the TG content in TG-rich lipoproteins (TRLs; ie, very low-density lipoproteins plus chylomicrons) and their remnants. There remains some uncertainty regarding the direct causal role of TRLs in the progression of atherosclerosis and CVD, with cardiovascular outcome studies of TG-lowering agents, to date, having produced inconsistent results. Although low-density lipoprotein cholesterol (LDL-C) remains the primary treatment target to reduce CVD risk, a number of large-scale epidemiological studies have shown that elevated TG levels are independently associated with increased incidence of cardiovascular events, even in patients treated effectively with statins. Genetic studies have further clarified the causal association between TRLs and CVD. Variants in several key genes involved in TRL metabolism are strongly associated with CVD risk, with the strength of a variant's effect on TG levels correlating with the magnitude of the variant's effect on CVD. TRLs are thought to contribute to the progression of atherosclerosis and CVD via a number of direct and indirect mechanisms. They directly contribute to intimal cholesterol deposition and are also involved in the activation and enhancement of several proinflammatory, proapoptotic, and procoagulant pathways. Evidence suggests that non-high-density lipoprotein cholesterol, the sum of the total cholesterol carried by atherogenic lipoproteins (including LDL, TRL, and TRL remnants), provides a better indication of CVD risk than LDL-C, particularly in patients with hypertriglyceridemia. This article aims to provide an overview of the available epidemiological, clinical, and genetic evidence relating to the atherogenicity of TRLs and their role in the progression of CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Proposed pathophysiology of triglyceride-rich lipoproteins in the progression of atherosclerosis. Note: Adapted by permission from Macmillan Publishers Ltd: [Nature Reviews Cardiology] Watts GF, Ooi EM, Chan DC. Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol. 2013;10(11):648–661,126 Copyright © 2013. Abbreviations: LPL, lipoprotein lipase; TRL, triglyceride-rich lipoproteins; TRL-R, triglyceride-rich lipoprotein remnants.](https://figures.cochat.ai/paper-figures/0257c3040d4b4514b3d59741a7e289ea/triglyceride-rich-lipoproteins-as-a-causal-factor-for-cardiovascular-disease-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Upon entering the arterial intima, these remnants are selectively retained through binding to extracellular matrix proteoglycans, prolonging their residence time in the subendothelial space. This retention facilitates uptake by resident macrophages via scavenger receptors, without requiring the oxidative modification typical of LDL particles.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Genetic studies and epidemiologic data increasingly implicate remnant lipoproteins as causal contributors to atherogenesis, providing a strong mechanistic and clinical rationale for targeted intervention [8–12].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“The elevated cholesterol content per remnant particle, compared to LDL, amplifies their contribution to lipid accumulation and foam cell formation, key early events in plaque development [17].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 1×
“It is also worth noting that LDL-C levels are ordinarily estimated by the Friedewald equation.(116) The Friedewald equation is inapplicable for patients with fasting TG .”
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
(1999) · The Lancet · doi:10.1016/s0140-6736(99)07072-5 · Cited by 3,812 · cited 1×
“The Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardio (GISSI)-Prevenzione Trial showed that in postMI patients, EPA and DHA significantly reduced the risk of reinfarction and death over a 3-year follow-up period.(97) Additionally, in the Japan EPA Lipid Intervention Study (JELIS), the addition o…”
BackgroundESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284 · cited 2×
“However, fenofibrate appears to be better tolerated than other fibrates, with no cases of rhabdomyolysis observed with fenofibrate–statin combination therapy in two large-scale clinical trials.(79,84) Fenofibrate is often recommended for use in combination with statin therapy in patients requiring additional non-HDL-C…”
Background2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 2×
“06) for reduction in cardiovascular risk.(84)”
BackgroundMajor lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516 · cited 1×
“98 Heterogeneity in results observed in cardiovascular outcome studies of TG-lowering agents may be due, in part, to the inclusion of subjects with normal baseline TG levels ( , 150 mg/dL [ , 1.7 mmol/L]).”
BackgroundInfluential(1999) · PubMed · Cited by 2,062
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · cited 2×
“That being said, these associations were not adjusted for other lipid parameters.(66,68) A number of studies have found that the association between plasma TG levels (both fasting and nonfasting) and cardiovascular risk is often attenuated once adjusted for other lipid parameters, including HDL-C and non-HDL-C.”
BackgroundTriglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619 · cited 2×
“006).(67) Likewise, two prospective cohort studies using data from the Copenhagen City Heart Study found that the cumulative incidence of cardiovascular events (ischemic stroke, MI, ischemic heart disease) and all-cause mortality were strongly associated with increasing nonfasting TG levels (all P,0.”
BackgroundTriglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419 · cited 2×
“TRL metabolism Cholesterol esters and TG are the two most important circulating lipids.(15) Owing to their hydrophobic nature, they are combined into lipoprotein particles in association with proteins that allow them to be transported in the plasma.”
Backgroundn-3 fatty acids and serum lipoproteins: human studies
Harris, W. (1997) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/65.5.1645s · Cited by 1,243 · cited 1×
“Higher doses of each formulation and higher baseline TG levels are associated with greater TG reductions.(96) Of note, DHA-containing formulations are thought to increase LPL expression, leading to increased TG removal from circulating VLDL and chylomicron particles.”
BackgroundChapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227 · cited 5×
“Plasma TG levels are known to correspond with the levels of TRLs and their remnants.(2) However, hypertriglyceridemia is also often accompanied by further lipoprotein disturbances, including increased very low-density lipoproteins (VLDLs) and total apolipoprotein (apo) C-III, elevated levels of small, dense LDL-C and…”
BackgroundInfluentialRemnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115 · cited 3×
“53 Key components of TRL metabolism have also been shown to be associated with CVD, in particular apoC-III, a key contributor to hypertriglyceridemia due to its inhibitory effects on LPL. 30,31,54 ApoC-III is thought to contribute to the progression of atherosclerosis via a number of mechanisms: 54 it can impair VLDL…”
BackgroundEndothelial dysfunction: cardiovascular risk factors, therapy, and outcome.
Hadi, H. A. R., Carr, C. S., & Suwaidi, J. M. S. A. (2005) · PubMed Central · Cited by 1,078
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Smith, S. C., Jr. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/ahxt-ag78 · Cited by 1,042
Wang, C., Harris, W. S., Chung, M., Lichtenstein, A. H., Balk, E. M., Kupelnick, B., Jordan, H. S., & Lau, J. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.1.5 · Cited by 980 · cited 1×
“103,104 107 Moreover, omega-3 fatty acids do not affect liver function and do not exhibit drug–drug interactions with other lipid-lowering agents, including statins.”
BackgroundSharrett, A. R., Ballantyne, C. M., Coady, S. A., Heiss, G., Sorlie, P. D., Catellier, D., & Patsch, W. (2001) · Circulation · doi:10.1161/hc3501.095214 · Cited by 944
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927 · cited 1×
“12 This, along with the fact that cardiovascular outcome studies of TG-lowering agents have produced inconsistent results, 13,14 means that there remains some uncertainty regarding the direct causal role of TRLs in the progression of atherosclerosis and CVD. 8 This review aims to provide an…”
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919 · cited 1×
“Similarly, a second study, which analyzed data from 75,725 participants, found that heterozygosity of loss-of-function mutations in APOC3 were associated with a mean reduction in nonfasting TG levels of 44% and a corresponding 41% decrease in the incidence of ischemic vascular disease compared with wild-type individua…”
ResultEvaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887 · cited 3×
“Therefore, the use of non-HDL-C as a treatment target is now advocated by several guidelines, particularly in patients with hypertriglyceridemia.(8,69,70) It is also worth noting that LDL-C levels are ordinarily estimated by the Friedewald equation.”
BackgroundCommon variants associated with plasma triglycerides and risk for coronary artery disease
Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2795 · Cited by 862 · cited 2×
“These results support the hypothesis that TRLs causally influence cardiovascular risk.(16) Sequence variants in several key genes involved in the metabolism of TRLs, such as those encoding LPL and the proteins that regulate it, appear to be strongly associated with CVD risk.”
Boekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., Simes, R. J., Durrington, P., Hitman, G. A., Welch, K. M. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.366 · Cited by 795 · cited 5×
“2,28 Additionally, although a number of guidelines recommend LDL-C as a primary treatment target, there is increasing evidence that non-HDL-C, the sum of the total cholesterol carried by all atherogenic lipoproteins (including LDL, IDL, and VLDL and chylomicrons and their remnants) provides a better indication of card…”
BackgroundInfluentialHigh-Density Lipoprotein Subfractions - What the Clinicians Need to Know
Pirillo, A., Norata, G. D., & Catapano, A. L. (2013) · Cardiology · doi:10.1159/000346463 · Cited by 748
Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review
Balk, E. M., Lichtenstein, A. H., Chung, M., Kupelnick, B., Chew, P., & Lau, J. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.02.012 · Cited by 732
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Varbo, A., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2013) · Circulation · doi:10.1161/circulationaha.113.003008 · Cited by 692 · cited 1×
“As this association was not observed for genetically elevated LDL-C, this suggests that the inflammatory component of atherosclerosis may be driven by elevated TRLs and remnant cholesterol.(63) Taken together, these findings are consistent with the hypothesis that elevated TG levels, and consequently TRLs, are causall…”
ResultHPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction
Do, R., Stitziel, N. O., Won, H.-H., Jørgensen, A. B., Duga, S., Angelica Merlini, P., Kiezun, A., Farrall, M., Goel, A., Zuk, O., et al. (2015) · Nature · doi:10.1038/nature13917 · Cited by 650
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635 · cited 8×
“7 mmol/L) is desirable, and if elevated TG or non-HDL-C levels remain following lifestyle intervention and statin therapy, a number of guidelines recommend the use of TG-lowering agents, primarily fibrates, niacin, or omega-3 fatty acids (Table 2).(2,4,8,70)”
BackgroundInfluentialMiller, M., Cannon, C. P., Murphy, S. A., Qin, J., Ray, K. K., & Braunwald, E. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.038 · Cited by 610 · cited 5×
“025).(10) A wealth of epidemiological evidence exists, demonstrating that both fasting and nonfasting TG levels are significant predictors of cardiovascular events, even in individuals who have already achieved guideline-recommended LDL-C levels with lipid-lowering therapy.”
BackgroundInfluentialRauch, B., Schiele, R., Schneider, S., Diller, F., Victor, N., Gohlke, H., Gottwik, M., Steinbeck, G., Del Castillo, U., Sack, R., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.948562 · Cited by 607
Nonfasting triglycerides and risk of ischemic stroke in the general population
Freiberg, J. J. (2008) · JAMA · doi:10.1001/jama.2008.621 · Cited by 542
Jellinger, P. S., Smith, D. A., Mehta, A. E., Ganda, O., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533 · cited 1×
“In such cases, guidelines recommend the initiation of TG-lowering therapy to reduce the risk of pancreatitis.(3,4,70) Guidelines also acknowledge that a TG level of ,150 mg/dL (,1.”
BackgroundJacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.07.007 · Cited by 462 · cited 5×
“In such cases, guidelines recommend the initiation of TG-lowering therapy to reduce the risk of pancreatitis.(3,4,70) Guidelines also acknowledge that a TG level of ,150 mg/dL (,1.”
BackgroundInfluentialTissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications
Steffel, J., Lüscher, T. F., & Tanner, F. C. (2006) · Circulation · doi:10.1161/circulationaha.105.567297 · Cited by 456 · cited 1×
“They have also been shown to upregulate the endothelial expression of tissue factor, a key initiator of the coagulation cascade.(44,45,51) Finally, TRL remnants suppress the atheroprotective and anti-inflammatory effects of HDL(52) and have been shown to significantly correlate with impairment of coronary vasodilation.”
BackgroundKamanna, V. S., & Kashyap, M. L. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.029 · Cited by 453
Sampson, U. K., Fazio, S., & Linton, M. F. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0219-7 · Cited by 439 · cited 2×
“Despite significant LDL-C lowering with statin therapy, substantial residual cardiovascular risk often remains.(5) This residual risk is thought to be due, in part, to inadequate reduction of LDL-C for a given level of risk, low levels of Vascular Health and Risk Management”
BackgroundEfficacy and safety of high-density lipoprotein cholesterol-increasing compounds
Birjmohun, R. S., Hutten, B. A., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.031 · Cited by 429 · cited 2×
“Niacin has been shown to decrease TG levels by 20%, LDL-C levels by 12%, and non-HDL-C levels by 7%–39% and to increase HDL-C levels by an average of 16%.(72,73) Despite improvements in coronary atherosclerosis and carotid intima-media thickness, niacin does not appear to impact risk for cardiovascular events when add…”
BackgroundMartin, S. S., Blaha, M. J., Elshazly, M. B., Brinton, E. A., Toth, P. P., McEvoy, J. W., Joshi, P. H., Kulkarni, K. R., Mize, P. D., Kwiterovich, P. O., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.079 · Cited by 428 · cited 1×
“Therefore, alternative evaluation is warranted in high-risk patients with elevated TG levels.(117,118)”
BackgroundSelf-citationSafety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408 · cited 1×
“Fibrate therapy is associated with a number of adverse effects, including increases in creatinine levels, myopathy, and, in rare cases, rhabdomyolysis, especially when used in combination with other lipid-lowering therapies.(79,81,82) Gemfibrozil, in particular, has been shown to increase exposure to and reduce the re…”
BackgroundGoldstein, J. L., Ho, Y. K., Brown, M. S., Innerarity, T. L., & Mahley, R. W. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85958-6 · Cited by 376
Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368 · cited 2×
“Niacin has been shown to decrease TG levels by 20%, LDL-C levels by 12%, and non-HDL-C levels by 7%–39% and to increase HDL-C levels by an average of 16%.(72,73) Despite improvements in coronary atherosclerosis and carotid intima-media thickness, niacin does not appear to impact risk for cardiovascular events when add…”
BackgroundBays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.04.015 · Cited by 358
GPIHBP1 Is Responsible for the Entry of Lipoprotein Lipase into Capillaries
Davies, B. S. J., Beigneux, A. P., Barnes, R. H., Tu, Y., Gin, P., Weinstein, M. M., Nobumori, C., Nyrén, R., Goldberg, I., Olivecrona, G., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.016 · Cited by 342 · cited 1×
“LPL is synthesized by myocytes and adipocytes before being transported to the lumen of the capillaries via GPIHBPI, a small glycosylphosphatidylinositol-anchored protein synthesized by the capillary endothelial cells.(24,25) LPL requires activation via apoC-II,(26) and its activity is highly regulated by various prote…”
BackgroundBallantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.031 · Cited by 342
Rapp, J. H., Lespine, A., Hamilton, R. L., Colyvas, N., Chaumeton, A. H., Tweedie-Hardman, J., Kotite, L., Kunitake, S. T., Havel, R. J., & Kane, J. P. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.11.1767 · Cited by 340
Nordestgaard, B. G., Wootton, R., & Lewis, B. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.4.534 · Cited by 334
Safety and Efficacy of Omacor in Severe Hypertriglyceridemia
Harris, W. S., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., Berglund, L., & Osmundsen, K. (1997) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182679700400511 · Cited by 306 · cited 1×
“Moreover, omega-3 fatty acids do not affect liver function and do not exhibit drug–drug interactions with other lipid-lowering agents, including statins.(108,109) They are metabolized by mitochondrial beta-oxidation.”
BackgroundKawakami, A., Aikawa, M., Alcaide, P., Luscinskas, F. W., Libby, P., & Sacks, F. M. (2006) · Circulation · doi:10.1161/circulationaha.106.622514 · Cited by 305 · cited 1×
“ApoC-III is thought to contribute to the progression of atherosclerosis via a number of mechanisms:(54) it can impair VLDL binding to cellular receptors, resulting in small, dense LDL particle formation,(12) and has been shown to induce the expression of proinflammatory mediators and to stimulate monocyte activation a…”
BackgroundWang, L., Gill, R., Pedersen, T. L., Higgins, L. J., Newman, J. W., & Rutledge, J. C. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m700505-jlr200 · Cited by 303
Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV.
Goldberg, I. J., Scheraldi, C. A., Yacoub, L. K., Saxena, U., & Bisgaier, C. L. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39557-2 · Cited by 291 · cited 1×
“24,25 LPL requires activation via apoC-II, 26 and its activity is highly regulated by various proteins, including apoC-III, apoA5, and angiopoietin-like proteins 3 and 4.”
BackgroundBruckert, E., Labreuche, J., & Amarenco, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.023 · Cited by 273
Schwartz, G. G., Abt, M., Bao, W., DeMicco, D., Kallend, D., Miller, M., Mundl, H., & Olsson, A. G. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.544 · Cited by 272 · cited 4×
“8 Severe hypertriglyceridemia, defined by the 2014 National Lipid Association guidelines as a TG level of $ 500 mg/dL ( $ 5.6 mmol/L), is a well-established risk factor for acute pancreatitis, 9 and moderately elevated TG levels have been shown to be independently associated with increased CVD risk, even in patients t…”
BackgroundInfluentialSafety considerations with niacin therapy
Guyton, J. R., & Bays, H. E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.018 · Cited by 269 · cited 2×
“The most common adverse effect, cutaneous vasodilatation or “flushing”, reportedly occurs in up to 70% of patients receiving niacin therapy(72) and often leads to treatment discontinuation.(4,91) Although attempts have been made to reduce the incidence of niacininduced flushing using laropiprant, a specific antagonist…”
BackgroundShin, H. K., Kim, Y. K., Kim, K. Y., Lee, J. H., & Hong, K. W. (2004) · Circulation · doi:10.1161/01.cir.0000117403.64398.53 · Cited by 268 · cited 1×
“TRL remnants have also been shown to induce endothelial cell apoptosis via increased secretion of the proapoptotic cytokines, tumor necrosis factor-α, and interleukin-1β, a process that is known to contribute to vascular injury and atherosclerosis.(49) TRLs and their remnants enhance platelet aggregation and clot form…”
BackgroundGenetic determinants of plasma triglycerides
Johansen, C. T., Kathiresan, S., & Hegele, R. A. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r009720 · Cited by 263 · cited 1×
“LPL requires activation via apoC-II,(26) and its activity is highly regulated by various proteins, including apoC-III, apoA5, and angiopoietin-like proteins 3 and 4.(27) The hydrolysis of chylomicrons via LPL results in the production of free fatty acids and chylomicron remnants.”
BackgroundGenetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease
Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260 · cited 7×
“However, hypertriglyceridemia is also often accompanied by further lipoprotein disturbances, including increased very low-density lipoproteins (VLDLs) and total apolipoprotein (apo) C-III, elevated levels of small, dense LDL-C and total LDL particles, and decreased levels of HDL-C, all of which have been shown to be a…”
BackgroundInfluentialNew Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism
Ginsberg, H. N. (2002) · Circulation · doi:10.1161/01.cir.0000035280.64322.31 · Cited by 255 · cited 1×
“TRLs are highly heterogeneous, differing in size, density, composition, and associated cardiovascular risk.(21) They are composed of a neutral core of TG and cholesterol esters and a surface monolayer comprising phospholipids, free cholesterol, and apos, which participate in the regulation of transport and metabolism…”
BackgroundLee, M., Saver, J. L., Towfighi, A., Chow, J., & Ovbiagele, B. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.020 · Cited by 240 · cited 1×
“3 mmol/L]), fibrate therapy was associated with a 25% decrease in vascular events, and in 5,068 patients with both high TG and low HDL-C levels (,40 mg/dL [1 mmol/L]), a 29% decrease in vascular events was observed.(80)”
BackgroundKastelein, J. J. P., Maki, K. C., Susekov, A., Ezhov, M., Nordestgaard, B. G., Machielse, B. N., Kling, D., & Davidson, M. H. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.10.003 · Cited by 233 · cited 1×
“The most common adverse effects associated with omega-3 fatty acids are gastrointestinal (such as nausea and diarrhea).(103,104) The rate of treatment discontinuation observed in clinical trials is similar between omega-3 fatty acid groups and placebo groups.”
BackgroundDoi, H., Kugiyama, K., Oka, H., Sugiyama, S., Ogata, N., Koide, S.-I., Nakamura, S.-I., & Yasue, H. (2000) · Circulation · doi:10.1161/01.cir.102.6.670 · Cited by 227 · cited 3×
“44,45 TRL remnants have also been shown to induce early monocyte and neutrophil activation.”
BackgroundInfluentialOmega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis
Kotwal, S., Jun, M., Sullivan, D., Perkovic, V., & Neal, B. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966168 · Cited by 201 · cited 2×
“006).(13) Notably, many of the clinical”
BackgroundLeukocyte Activation by Triglyceride-Rich Lipoproteins
Alipour, A., van Oostrom, A. J. H. H. M., Izraeljan, A., Verseyden, C., Collins, J. M., Frayn, K. N., Plokker, T. W. M., Elte, J. W. F., & Castro Cabezas, M. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.159749 · Cited by 201 · cited 1×
“TRL remnants have also been shown to induce early monocyte and neutrophil activation.(47) Additionally, TRL remnants are known to increase the production of reactive oxygen species, which can increase vascular endothelial permeability, promote leukocyte adhesion, and, at high concentrations, cause cellular injury and…”
BackgroundGinsberg, H. N. (1998) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70023-2 · Cited by 194 · cited 1×
“Here, they are incorporated into chylomicrons, which are large apoB 48 containing lipoproteins with a large TG core (80%–95%).(23) Newly synthesized chylomicrons are then exported via perimesenteric lymphatics before entering the circulation, where they acquire apoC-II, apoC-III, and apoE.”
BackgroundGemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
Kyrklund, C. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00052-3 · Cited by 189 · cited 1×
“79,81,82 Gemfibrozil, in particular, has been shown to increase exposure to and reduce the renal clearance of statins by inhibiting their glucuronidation, 83 potentially leading to severe side effects.”
BackgroundThe Current State of Niacin in Cardiovascular Disease Prevention
Lavigne, P. M., & Karas, R. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.030 · Cited by 185
Relationship of Lipoproteins to Cardiovascular Events
Guyton, J. R., Slee, A. E., Anderson, T., Fleg, J. L., Goldberg, R. B., Kashyap, M. L., Marcovina, S. M., Nash, S. D., O'Brien, K. D., Weintraub, W. S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.023 · Cited by 182 · cited 1×
“05).(90) The use of niacin is often limited due to the high incidence of associated adverse effects.”
BackgroundGene therapy for lipoprotein lipase deficiency
Gaudet, D., Méthot, J., & Kastelein, J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283555a7e · Cited by 178 · cited 1×
“Intramuscular administration of alipogene tiparvovec has been shown to be generally well tolerated and is associated with clinical improvement and reduced incidence and severity of acute pancreatitis.(112) Mipomersen and lomitapide are both approved by the US Food and Drug Administration for the treatment of”
BackgroundLow nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study
Thomsen, M., Varbo, A., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2013.219881 · Cited by 171 · cited 4×
“53 Key components of TRL metabolism have also been shown to be associated with CVD, in particular apoC-III, a key contributor to hypertriglyceridemia due to its inhibitory effects on LPL. 30,31,54 ApoC-III is thought to contribute to the progression of atherosclerosis via a number of mechanisms: 54 it can impair VLDL…”
BackgroundInfluentialGower, R. M., Wu, H., Foster, G. A., Devaraj, S., Jialal, I., Ballantyne, C. M., Knowlton, A. A., & Simon, S. I. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.215434 · Cited by 160
Faergeman, O., Holme, I., Fayyad, R., Bhatia, S., Grundy, S. M., Kastelein, J. J. P., LaRosa, J. C., Larsen, M. L., Lindahl, C., Olsson, A. G., et al. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.04.008 · Cited by 154
Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy
Chang, J. T., Staffa, J. A., Parks, M., & Green, L. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.977 · Cited by 152 · cited 2×
“Gemfibrozil, in particular, has been shown to increase exposure to and reduce the renal clearance of statins by inhibiting their glucuronidation,(83) potentially leading to severe side effects.(82) However, fenofibrate appears to be better tolerated than other fibrates, with no cases of rhabdomyolysis observed with fe…”
BackgroundTriglyceride-Rich Lipoprotein Remnant Particles and Risk of Atherosclerosis
Hodis, H. N. (1999) · Circulation · doi:10.1161/01.cir.99.22.2852 · Cited by 149 · cited 1×
“Proposed pathophysiology of TRLs in the progression of atherosclerosis Evidence suggests that TRLs and their remnants and specific markers of TG metabolism, such as LPL and apoC-III, contribute to the progression of atherosclerosis and CVD both directly and indirectly.(12,32) These proposed pathophysiological mechanis…”
BackgroundPitas, R. E., Innerarity, T. L., & Mahley, R. W. (1983) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.3.1.2 · Cited by 147
Nordestgaard, B. G., Stender, S., & Kjeldsen, K. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.4.421 · Cited by 137
Brahm, A., & Hegele, R. (2013) · Nutrients · doi:10.3390/nu5030981 · Cited by 136
Wyler von Ballmoos, M. C., Haring, B., & Sacks, F. M. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.05.002 · Cited by 134
Gut-liver interaction in triglyceride-rich lipoprotein metabolism
Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 127 · cited 2×
“21 They are composed of a neutral core of TG and cholesterol esters and a surface monolayer comprising phospholipids, free cholesterol, and apos, which participate in the regulation of transport and metabolism of the TRL. 22 The metabolism of TRLs occurs via two principal pathways, an exogenous pathway that originates…”
BackgroundFilion, K. B., El Khoury, F., Bielinski, M., Schiller, I., Dendukuri, N., & Brophy, J. M. (2010) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-10-24 · Cited by 124 · cited 1×
“103,104 107 Moreover, omega-3 fatty acids do not affect liver function and do not exhibit drug–drug interactions with other lipid-lowering agents, including statins.”
BackgroundJellinger, P. S., Smith, D. A., Mehta, A., Ganda, O. P., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., Seibel, J. A., Kreisberg, R. A., & Goldberg, R. B. (2012) · Endocrine Practice · doi:10.4158/ep.18.2.269 · Cited by 123
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
(2012) · New England Journal of Medicine · doi:10.1056/nejmx120034 · Cited by 121
Demystifying the management of hypertriglyceridaemia
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115
Kostapanos, M. S., Milionis, H. J., & Elisaf, M. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/13168600-000000000-00000 · Cited by 113 · cited 1×
“Moreover, omega-3 fatty acids do not affect liver function and do not exhibit drug–drug interactions with other lipid-lowering agents, including statins.(108,109) They are metabolized by mitochondrial beta-oxidation.”
BackgroundEffects of VLDL and remnant particles on platelets.
Olufadi, R., & Byrne, C. D. (2006) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000093221 · Cited by 111 · cited 1×
“TRLs and their remnants enhance platelet aggregation and clot formation and amplify the coagulation cascade by 1) supporting the assembly of the prothombinase complex and 2) upregulating the expression of plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1 antigen.(50) They have also been shown to…”
BackgroundChapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E. A. A., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(11)70033-2 · Cited by 109
Hua, S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00127 · Cited by 107 · cited 1×
“These proatherogenic adhesion molecules facilitate the transendothelial migration of leukocytes to sites of inflammation.(46) Consequently, their TRL remnantmediated activation leads to endothelial monocyte adhesion and an enhanced inflammatory response.”
BackgroundKONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 103
IRF-1 and miRNA126 Modulate VCAM-1 Expression in Response to a High-Fat Meal
Sun, C., Alkhoury, K., Wang, Y. I., Foster, G. A., Radecke, C. E., Tam, K., Edwards, C. M., Facciotti, M. T., Armstrong, E. J., Knowlton, A. A., et al. (2012) · Circulation Research · doi:10.1161/circresaha.112.270314 · Cited by 101 · cited 1×
“12 Oxidized free fatty acids are known to increase the expression of inflammatory interleukins and cytokines, leading to endothelial inflammation, 41–43 while TRL remnants have been shown to upregulate the endothelial expression of intercellular adhesion molecule-1 and vascular cell adhesion…”
BackgroundYlä-Herttuala, S., Jaakkola, O., Ehnholm, C., Tikkanen, M. J., Solakivi, T., Särkioja, T., & Nikkari, T. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38503-5 · Cited by 100
Zheng, X.-Y., & Liu, L. (2007) · Journal of Lipid Research · doi:10.1194/jlr.r700001-jlr200 · Cited by 97 · cited 1×
“Finally, TRL remnants suppress the atheroprotective and anti-inflammatory effects of HDL(52) and have been shown to significantly correlate with impairment of coronary vasodilation.(53) Key components of TRL metabolism have also been shown to be associated with CVD, in particular apoC-III, a key contributor to hypertr…”
BackgroundPatel, S., Puranik, R., Nakhla, S., Lundman, P., Stocker, R., Wang, X., Lambert, G. C., Rye, K.-A., Barter, P. J., Nicholls, S. J., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.07.047 · Cited by 92
Andersson, C., Lyass, A., Vasan, R. S., Massaro, J. M., D’Agostino, R. B., & Robins, S. J. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.08.007 · Cited by 86
Apolipoprotein CIII promotes Ca 2+ -dependent β cell death in type 1 diabetes
Juntti-Berggren, L., Refai, E., Appelskog, I., Andersson, M., Imreh, G., Dekki, N., Uhles, S., Yu, L., Griffiths, W. J., Zaitsev, S., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403551101 · Cited by 86
Aung, H. H., Lame, M. W., Gohil, K., An, C.-I., Wilson, D. W., & Rutledge, J. C. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301375 · Cited by 86 · cited 1×
“TRL remnants have also been shown to promote endothelial dysfunction, which potentiates atherogenesis.(40) VLDL”
BackgroundTriglycerides and cardiovascular disease
Esan, O., & Wierzbicki, A. S. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000862 · Cited by 81
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
Moneta, G. L. (2010) · Yearbook of Vascular Surgery · doi:10.1016/s0749-4041(10)79320-9 · Cited by 77
Overview of Prescription Omega-3 Fatty Acid Products for Hypertriglyceridemia
Weintraub, H. S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2828 · Cited by 73
The importance of triglycerides: Results from the prospective cardiovascular M�nster (PROCAM) study
Assmann, G., & Schulte, H. (1992) · European Journal of Epidemiology · doi:10.1007/bf00145359 · Cited by 73
The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis
Brunzell, J. D., & Schrott, H. G. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.06.005 · Cited by 71 · cited 1×
“…2014 National Lipid Association guidelines as a TG level of $ 500 mg/dL ( $ 5.6 mmol/L), is a well-established risk factor for acute pancreatitis, 9 and moderately elevated TG levels have been shown to be independently associated with increased CVD risk, even in patients treated effectively with…”
BackgroundInfluentialApolipoprotein C-III: Going Back to the Future for a Lipid Drug Target
Huff, M. W., & Hegele, R. A. (2013) · Circulation Research · doi:10.1161/circresaha.113.301464 · Cited by 70 · cited 1×
“However, concerns have been raised that the inhibition of hepatic apoC-III synthesis could lead to hepatic lipid accumulation.(111) Another agent with promise in reducing TG levels is alipogene tiparvovec (AAV1-LPLS447X), a nonreplicating and nonreplacing adeno-associated viral vector that delivers copies of the human…”
BackgroundWang, Y. I., Bettaieb, A., Sun, C., DeVerse, J. S., Radecke, C. E., Mathew, S., Edwards, C. M., Haj, F. G., Passerini, A. G., & Simon, S. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078322 · Cited by 65 · cited 3×
“Oxidized free fatty acids are known to increase the expression of inflammatory interleukins and cytokines, leading to endothelial inflammation, while TRL remnants have been shown to upregulate the endothelial expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1.(44,45) These proatherog…”
BackgroundFolsom, A. R., Peacock, J. M., Demerath, E., & Boerwinkle, E. (2008) · Metabolism · doi:10.1016/j.metabol.2008.06.016 · Cited by 64 · cited 1×
“Finally, loss-of-function variants in the gene encoding angiopoietinlike protein 4 (ANGPTL4), an inhibitor of LPL, were found to be associated with substantially decreased TG levels and decreased coronary heart disease risk.(62) Genetically elevated levels of TG and remnant lipoprotein cholesterol are also associated…”
BackgroundTrends in elevated triglyceride in adults: United States, 2001-2012.
Carroll, M. D., Kit, B. K., & Lacher, D. A. (2015) · PubMed · Cited by 64
Farnier, M. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3390 · Cited by 63
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The University of North Carolina at Chapel Hill University Libraries (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/tchk-ac83 · Cited by 60
Beigneux, A. P., Davies, B. S. J., Bensadoun, A., Fong, L. G., & Young, S. G. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800030-jlr200 · Cited by 59
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Toth, P. P. (2010) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(10)79553-6 · Cited by 55
Self-citationToth, P. P. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.05.028 · Cited by 55
Self-citationEffects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects
Davidson, M. H., Bays, H. E., Stein, E., Maki, K. C., Shalwitz, R. A., & Doyle, R. (2006) · Clinical Cardiology · doi:10.1002/clc.4960290609 · Cited by 51 · cited 1×
“Of note, however, fibrate-induced increases in LDL-C may occur in patients with severe hypertriglyceridemia.(74,75) To date, cardiovascular outcome studies of fibrates have produced varied results, with some studies suggesting a small benefit, particularly in patients with other factors besides hypertriglyceridemia, s…”
ResultDetrimental Effects of Apolipoprotein E4: Potential Therapeutic Targets in Alzheimers Disease
Mahley, R., Huang, Y., & Weisgraber, K. (2007) · Current Alzheimer Research · doi:10.2174/156720507783018334 · Cited by 51
Zheng, C. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000040 · Cited by 50 · cited 1×
“In addition to size, lipoproteins may also be characterized by the apos they contain, with apoB100 (also known as apoB) being associated with VLDL and LDL and apoA-I associated with HDL.(17) There are several other apos involved in lipoprotein metabolism, many of which are thought to potentially contribute to a number…”
BackgroundEpidemiology of coronary heart disease in patients with human immunodeficiency virus.
Triant, V. A. (2014) · PubMed · doi:10.3908/ricm15s1s002 · Cited by 41
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke‐Schmidt, R., & Nordestgaard, B. G. (2014) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2014.08.087 · Cited by 41
Toth, P. P. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.02.004 · Cited by 39 · cited 5×
“Mipomersen is an antisense oligonucleotide that blocks the translation of the apoB-100 gene, reducing its synthesis and consequently decreasing the circulation of atherogenic apoB-100containing lipoproteins, including VLDL, IDL, and LDL.(113) Lomitapide is a microsomal TG transfer protein inhibitor that blocks the mic…”
BackgroundInfluentialSelf-citationBatt, K., Patel, L., Botham, K., & Suckling, K. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0551-2 · Cited by 38 · cited 1×
“In contrast to LDL, TRL remnants can be taken up directly by arterial macrophages without oxidative modification 37–39 and, due to their larger size, carry more cholesterol per particle than LDL. 12 TRL remnants have also been shown to promote endothelial dysfunction, which potentiates…”
BackgroundMorton, A. M., Furtado, J. D., Lee, J., Amerine, W., Davidson, M. H., & Sacks, F. M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.09.005 · Cited by 33
NON-FASTING TRIGLYCERIDES AND RISK OF ISCHEMIC STROKE IN THE GENERAL POPULATION
Nordestgaard, B. G., Freiberg, J., Jensen, J. S., & Tybjærg‐Hansen, A. (2008) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(08)70057-6 · Cited by 27 · cited 1×
“That being said, these associations were not adjusted for other lipid parameters.(66,68) A number of studies have found that the association between plasma TG levels (both fasting and nonfasting) and cardiovascular risk is often attenuated once adjusted for other lipid parameters, including HDL-C and non-HDL-C.”
BackgroundRole of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cells
Sol, E.-R. M., Sundsten, T., & Bergsten, P. (2009) · Lipids in Health and Disease · doi:10.1186/1476-511x-8-3 · Cited by 26
Fazekas, F., Enzinger, C., Ropele, S., Schmidt, H., Schmidt, R., & Strasser‐Fuchs, S. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.08.018 · Cited by 24
Hermans, M. P., Ahn, S. A., & Rousseau, M. F. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-56 · Cited by 19 · cited 1×
“Therefore, alternative evaluation is warranted in high-risk patients with elevated TG levels.(117,118)”
BackgroundToth, P. P., Shah, P. K., Wilkinson, M. J., Davidson, M. H., & McCullough, P. A. (2014) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0702 · Cited by 6
Self-citationApolipoprotein C III promotes Ca2+ dependent beta-cell death in type 1 diabetes
Juntti‐Berggren, L., Refai, E., Appelskog, I. B., Andersson, M., Imreh, G., Dekki, M., Uhles, S., Yu, L., Griffiths, W., Zaitsev, S., et al. (2004) · UCL Discovery (University College London) · Cited by 4
Toth, P. P. (2010) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(10)79530-5 · Cited by 3
Self-citationGaudet, D., Alexander, V. J., Brisson, D., Tremblay, K., Flaim, J., Hughes, S. G., Singleton, W., & Geary, R. S. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.02.090 · Cited by 2 · cited 1×
“Phase II clinical trials conducted in patients with LPL deficiency demonstrated that Volanesorsen successfully reduced levels of apoC-III, TG, and non-HDL-C.(110) However, concerns have been raised that the inhibition of hepatic apoC-III synthesis could lead to hepatic lipid accumulation.”
Background
Cited by
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Multi-organ proteomic landscape of COVID-19 autopsies
Nie, X., Qian, L., Sun, R., Huang, B., Dong, X., Xiao, Q., Zhang, Q., Lu, T., Yue, L., Chen, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.004 · Cited by 408
Hypertriglyceridaemia and risk of coronary artery disease
Reiner, Ž. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.31 · Cited by 387
Virani, S. S., Morris, P. B., Agarwala, A., Ballantyne, C. M., Birtcher, K. K., Kris-Etherton, P. M., Ladden-Stirling, A. B., Miller, M., Orringer, C. E., & Stone, N. J. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.011 · Cited by 341
Hypertriglyceridemia and atherosclerosis
Peng, J., Luo, F., Ruan, G., Peng, R., & Li, X. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0625-0 · Cited by 245
“Additionally, the severe hypertriglyceridemia mainly contains CM that leads to pancreatitis [43], and the hydrolysis of CM via LPL results in the production of free fatty acids and chylomicron remnants which can contribute to pancreatitis [44].”
Background
Metadata
- Authors
- Toth, P.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Toth, Peter
- ORCID
- Toth, Peter
- Venue
- Vascular Health and Risk Management
- Publisher
- Informa UK Limited
- Published
- 2016-05
- Volume
- 12
- Pages
- 171
- ISSN
- 1176-6344 (ISSN-L)
- 1178-2048
- PMC
- PMC4866746
- OpenAlex
- W2345841042
- Cited by
- 237
- References
- 149
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 11 · 2023: 18 · 2022: 27 · 2021: 34 · 2020: 29 · 2019: 22 · 2018: 29 · 2017: 22 · 2016: 8
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Vascular Health and Risk Management (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- triglyceride-rich lipoproteins, hypertriglyceridemia, cardiovascular risk, atherosclerosis, VLDL, chylomicrons, acute pancreatitis, non-HDL cholesterol, genetic variants, statin therapy, pro-inflammatory pathways, LDL cholesterol
- MeSH terms
- Animals, Hypolipidemic Agents, Cardiovascular Diseases, Humans, Lipoproteins, Phenotype, Risk Factors, Triglycerides, Hypertriglyceridemia, Biomarkers, Treatment Outcome, Disease Progression, Risk Assessment, Genetic Predisposition to Disease, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.